Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 70.53
OCLS's Cash to Debt is ranked higher than
65% of the 702 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. OCLS: 70.53 )
Ranked among companies with meaningful Cash to Debt only.
OCLS' s 10-Year Cash to Debt Range
Min: 1.04  Med: 9.07 Max: No Debt
Current: 70.53
Equity to Asset 0.80
OCLS's Equity to Asset is ranked higher than
77% of the 563 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. OCLS: 0.80 )
Ranked among companies with meaningful Equity to Asset only.
OCLS' s 10-Year Equity to Asset Range
Min: -0.11  Med: 0.55 Max: 0.8
Current: 0.8
-0.11
0.8
F-Score: 3
Z-Score: -9.23
M-Score: -2.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -48.07
OCLS's Operating margin (%) is ranked lower than
88% of the 660 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.81 vs. OCLS: -48.07 )
Ranked among companies with meaningful Operating margin (%) only.
OCLS' s 10-Year Operating margin (%) Range
Min: -1202.95  Med: -76.94 Max: -7.35
Current: -48.07
-1202.95
-7.35
Net-margin (%) -59.21
OCLS's Net-margin (%) is ranked lower than
90% of the 661 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.92 vs. OCLS: -59.21 )
Ranked among companies with meaningful Net-margin (%) only.
OCLS' s 10-Year Net-margin (%) Range
Min: -1219.03  Med: -96.64 Max: 27.33
Current: -59.21
-1219.03
27.33
ROE (%) -69.85
OCLS's ROE (%) is ranked lower than
92% of the 685 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.31 vs. OCLS: -69.85 )
Ranked among companies with meaningful ROE (%) only.
OCLS' s 10-Year ROE (%) Range
Min: -1759.66  Med: -190.65 Max: 46.27
Current: -69.85
-1759.66
46.27
ROA (%) -47.72
OCLS's ROA (%) is ranked lower than
93% of the 706 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.19 vs. OCLS: -47.72 )
Ranked among companies with meaningful ROA (%) only.
OCLS' s 10-Year ROA (%) Range
Min: -1518.83  Med: -99.82 Max: 22.39
Current: -47.72
-1518.83
22.39
ROC (Joel Greenblatt) (%) -758.84
OCLS's ROC (Joel Greenblatt) (%) is ranked lower than
90% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.13 vs. OCLS: -758.84 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OCLS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1665.34  Med: -691.39 Max: 541.28
Current: -758.84
-1665.34
541.28
Revenue Growth (3Y)(%) -24.00
OCLS's Revenue Growth (3Y)(%) is ranked lower than
92% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. OCLS: -24.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OCLS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -27.3  Med: -4.60 Max: 53.6
Current: -24
-27.3
53.6
EBITDA Growth (3Y)(%) -19.10
OCLS's EBITDA Growth (3Y)(%) is ranked lower than
81% of the 483 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. OCLS: -19.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OCLS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -34.70 Max: 372
Current: -19.1
0
372
EPS Growth (3Y)(%) -23.10
OCLS's EPS Growth (3Y)(%) is ranked lower than
79% of the 452 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.20 vs. OCLS: -23.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OCLS' s 10-Year EPS Growth (3Y)(%) Range
Min: -54.1  Med: -25.40 Max: 356.8
Current: -23.1
-54.1
356.8
» OCLS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with OCLS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.79
OCLS's P/B is ranked higher than
74% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.42 vs. OCLS: 1.79 )
Ranked among companies with meaningful P/B only.
OCLS' s 10-Year P/B Range
Min: 0.88  Med: 7.80 Max: 264.25
Current: 1.79
0.88
264.25
P/S 0.98
OCLS's P/S is ranked higher than
83% of the 653 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.30 vs. OCLS: 0.98 )
Ranked among companies with meaningful P/S only.
OCLS' s 10-Year P/S Range
Min: 0.49  Med: 3.47 Max: 18.2
Current: 0.98
0.49
18.2
EV-to-EBIT -1.89
OCLS's EV-to-EBIT is ranked lower than
180% of the 489 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.18 vs. OCLS: -1.89 )
Ranked among companies with meaningful EV-to-EBIT only.
OCLS' s 10-Year EV-to-EBIT Range
Min: -11.1  Med: -4.10 Max: -0.1
Current: -1.89
-11.1
-0.1
Current Ratio 3.74
OCLS's Current Ratio is ranked higher than
68% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. OCLS: 3.74 )
Ranked among companies with meaningful Current Ratio only.
OCLS' s 10-Year Current Ratio Range
Min: 1.16  Med: 2.01 Max: 3.74
Current: 3.74
1.16
3.74
Quick Ratio 3.19
OCLS's Quick Ratio is ranked higher than
71% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.66 vs. OCLS: 3.19 )
Ranked among companies with meaningful Quick Ratio only.
OCLS' s 10-Year Quick Ratio Range
Min: 0.95  Med: 1.94 Max: 3.19
Current: 3.19
0.95
3.19
Days Inventory 70.95
OCLS's Days Inventory is ranked higher than
73% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.56 vs. OCLS: 70.95 )
Ranked among companies with meaningful Days Inventory only.
OCLS' s 10-Year Days Inventory Range
Min: 35.89  Med: 47.38 Max: 76.35
Current: 70.95
35.89
76.35
Days Sales Outstanding 39.97
OCLS's Days Sales Outstanding is ranked higher than
78% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.45 vs. OCLS: 39.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
OCLS' s 10-Year Days Sales Outstanding Range
Min: 39.97  Med: 62.53 Max: 151.99
Current: 39.97
39.97
151.99

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.81
OCLS's Price/Net Cash is ranked higher than
67% of the 171 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.52 vs. OCLS: 6.81 )
Ranked among companies with meaningful Price/Net Cash only.
OCLS' s 10-Year Price/Net Cash Range
Min: 4  Med: 8.81 Max: 18.1
Current: 6.81
4
18.1
Price/Net Current Asset Value 3.25
OCLS's Price/Net Current Asset Value is ranked higher than
81% of the 361 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.04 vs. OCLS: 3.25 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OCLS' s 10-Year Price/Net Current Asset Value Range
Min: 1.91  Med: 8.08 Max: 63.95
Current: 3.25
1.91
63.95
Price/Tangible Book 1.79
OCLS's Price/Tangible Book is ranked higher than
77% of the 614 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.15 vs. OCLS: 1.79 )
Ranked among companies with meaningful Price/Tangible Book only.
OCLS' s 10-Year Price/Tangible Book Range
Min: 1.05  Med: 5.09 Max: 31.27
Current: 1.79
1.05
31.27
Price/Median PS Value 0.29
OCLS's Price/Median PS Value is ranked higher than
97% of the 560 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. OCLS: 0.29 )
Ranked among companies with meaningful Price/Median PS Value only.
OCLS' s 10-Year Price/Median PS Value Range
Min: 0.17  Med: 1.10 Max: 4.87
Current: 0.29
0.17
4.87
Earnings Yield (Greenblatt) (%) -52.90
OCLS's Earnings Yield (Greenblatt) (%) is ranked lower than
98% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. OCLS: -52.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OCLS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -204.1  Med: 0.00 Max: 4.4
Current: -52.9
-204.1
4.4

Analyst Estimate

Mar16 Mar17 Mar18
Revenue(Mil) 16 18 24
EPS($) -0.37 -0.35 -0.07
EPS without NRI($) -0.37 -0.35 -0.07

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:O8Z1.Germany,
Oculus Innovative Sciences Inc was incorporated under the laws of the State of California in April 1999 as Micromed Laboratories, Inc. In August 2001, it changed its name to Oculus Innovative Sciences, Inc. In December 2006, it reincorporated under the laws of the State of Delaware. The Company develops, manufactures and markets a family of tissue care products that cure infections and, through a separate mechanism of action, enhance healing while reducing the need for antibiotics. Infection is a serious potential complication in both chronic and acute wounds, and controlling infection is a critical step in wound healing. The Company's platform technology, called Microcyn(r), is a proprietary solution of electrically charged oxychlorine small molecules designed to treat a wide range of organisms that cause disease (pathogens). These include viruses, fungi, spores and antibiotic-resistant strains of bacteria, such as methicillin-resistant Staphylococcus aureus, or MRSA, and vancomycin-resistant Enterococcus, or VRE, in wounds, as well as Clostridium difficile (C. diff), a highly contagious bacteria spread by human contact. The Company's products compete with a variety of products used for wound cleaning, debriding and moistening, including sterile saline, and chlorhexadine-based products, and they also compete with a large number of prescription and over-the-counter products for the prevention and treatment of infections, including topical anti-infectives, such as Betadine, silver sulfadiazine, hydrogen peroxide, Dakin's solution and hypochlorous acid, and topical antibiotics, such as Neosporine, Mupirocin and Bacitracin. Government authorities in the United States at the federal, state and local levels and foreign countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, distribution, sampling, marketing, and import and export of pharmaceutical products, biologics and medical devices.
» More Articles for OCLS

Headlines

Articles On GuruFocus.com
Experience a Unique Realm Of Science Fiction With Sony’s Virtual Reality Headset Mar 12 2015 
?? Feb 27 2015 
Focus on New Technologies Can Drive Facebook's Growth Jan 22 2015 
Oculus Innovative Sciences Inc. Reports Operating Results (10-Q) Feb 04 2011 
Oculus Innovative Sciences Inc. Reports Operating Results (10-Q) Nov 04 2010 
Oculus Innovative Sciences Inc. (OCLS) COO James J Schutz buys 18,500 Shares Aug 09 2010 
Oculus Innovative Sciences Inc. (OCLS) COO James J Schutz buys 18,500 Shares Aug 09 2010 
Oculus Innovative Sciences Inc. Reports Operating Results (10-Q) Aug 05 2010 
Oculus Innovative Sciences Inc. Reports Operating Results (10-Q) Feb 11 2010 
Oculus Innovative Sciences Inc. (OCLS) COO James J Schutz buys 20,000 Shares Dec 09 2009 

More From Other Websites
Oculus Innovative Sciences Reports Financial Results for the First Quarter of Fiscal Year 2016 Jul 30 2015
Oculus Innovative Sciences Inc Earnings Call scheduled for 4:30 pm ET today Jul 30 2015
OCULUS INNOVATIVE SCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 30 2015
Oculus Innovative Sciences Reports Financial Results for the First Quarter of Fiscal Year 2016 Jul 30 2015
Q1 2016 Oculus Innovative Sciences Inc Earnings Release - After Market Close Jul 30 2015
CONMED (CNMD) Posts Q2 Earnings, Revenue Miss; Down Y/Y - Analyst Blog Jul 22 2015
Oculus Innovative Sciences: The Cheapest Stock Available In An Active Dermatology Sector And A New... Jul 21 2015
Oculus Innovative Sciences Announces Fiscal First Quarter 2016 Financial Results and Conference Call Jul 16 2015
Oculus Innovative Sciences Announces Fiscal First Quarter 2016 Financial Results and Conference Call Jul 16 2015
A Dozen Reasons To Love Dermatology Companies Jul 14 2015
Company News for July 09, 2015 - Corporate Summary Jul 09 2015
LabCorp, Epic Sciences Ink Deal for Oncology Testing in Asia - Analyst Blog Jul 08 2015
Occulus Innovative Sciences (OCLS) Stock Spikes After Receiving New U.S. Patent Jul 08 2015
Oculus Innovative Sciences Receives New U.S. Patent for Microcyn® Technology in Treatment of Atopic... Jul 08 2015
Oculus Innovative Sciences Receives New U.S. Patent for Microcyn(R) Technology in Treatment of... Jul 08 2015
OCULUS INNOVATIVE SCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... Jul 02 2015
Coverage initiated on Oculus Innovative Sciences by Maxim Group Jun 26 2015
10-K for Oculus Innovative Sciences, Inc. Jun 18 2015
Oculus Innovative Sciences Regains Compliance With NASDAQ Minimum Bid Price Rule Jun 18 2015
Oculus Innovative Sciences Regains Compliance With NASDAQ Minimum Bid Price Rule Jun 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK